| 摘要 |
PROBLEM TO BE SOLVED: To provide a transepicutaneous administration form for treating restless leg syndrome. SOLUTION: The invention relates to a transepicutaneous pharmaceutical composition comprising rotigotine for the effective treatment of Restless Leg Syndrome (RLS), in particular in the form of an acrylate- or silicone-based Transdermal absorption therapeutic system (TDS) having a surface area of 2.5 to 20 cm<SP>2</SP>and containing 1.125 to 9.0 mg/cm<SP>2</SP>of rotigotine as its active component against the Restless Leg Syndrome, the system leading in the human Restless Leg Syndrome condition to an improvement, compared to a placebo treatment, by 2 or more units on the International Restless Leg Syndrome Study Group (IRLSSG) scale after administration over a period of eight days. COPYRIGHT: (C)2010,JPO&INPIT |
